Advertisement

Masthead

Articles in Press

Issue Highlights

Specialty Updates

Youth And Children Update: Breast Milk and Breastfeeding: Benefits, Barriers, Predictors, and Opportunities for Innovation

Sarbattama Sen, MD

Sarbattama Sen, MD 

Gastroenterology Update: Food As Medicine

A. Sidney Barritt IV, MD, MSCR

A. Sidney Barritt IV, MD, MSCR

Recipient of the 2022 Health Economics and Outcomes Research Application Award

Tara Lavelle
Assistant Professor, Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA

We, the Editorial Board of Clinical Therapeutics, are pleased to recognize Tara Lavelle, PhD, Topic Editor for Pharmacoeconomics, Outcomes, and Health Policy, as the recipient of the 2022 ISPOR Health Economics and Outcomes Research - Application Award. This award recognizes honorees for their outstanding practical application of HEOR in healthcare decision-making. The 2022 honoree is: Tara Lavelle, 2022 HEOR Award Recipient

About

Clinical Therapeutics

Cover Image - Clinical Therapeutics, Volume 44, Issue 10

Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.

Special Themed Issue on Rheumatoid Arthritis

Prevention of Rheumatoid Arthritis: Challenges and Opportunities to Change the Paradigm of Disease Management

Rheumatoid arthritis (RA) is a debilitating autoimmune disease that leads to chronic synovitis, systemic inflammation, and comorbidities which together impair quality of life and increase mortality risk. Recent advances in the understanding of RA etiology and pathogenesis suggest that prevention of RA onset in at-risk individuals may be an attainable goal. This themed issue of Clinical Therapeutics features expert perspectives on the opportunities, challenges, and progress toward development of preventive approaches for RA. Articles are accessible to all.

Monkeypox Information Center

Visit the Elsevier Information Center to find the most relevant research on Monkeypox, freely available here.

Novel Coronavirus Information Center

Visit the Elsevier Information Center to find the most relevant research on Novel Coronavirus (SARS-CoV-2), freely available here.

Metrics

Metrics

##
Impact Factor
##
5-Year Impact Factor
##
Eigenfactor Score

Introducing the Editorial team

Jill L. Maron, MD, MPH

Jill L. Maron, MD, MPH
Co-Editor-in-Chief

Dr. Jill Maron is a Professor of Pediatrics at the Warren Alpert Medical School of Brown University. She completed her undergraduate education at Harvard University (Cambridge, MA), receiving her bachelor’s degree in Biological Anthropology cum laude. She earned both a MD and MPH degree in International Health and Development from Tulane University (New Orleans, LA) prior to completing her Pediatrics training at Hasbro Children’s Hospital at Brown University (Providence, RI). Dr. Maron completed her fellowship in Newborn Medicine at the Floating Hospital for Children at Tufts Medical Center.

Paul Beninger, MD, MBA

Paul Beninger, MD, MBA
Co-Editor-in-Chief

Dr. Beninger is an Associate Professor of Public Health & Community Medicine at Tufts University School of Medicine, where he is the Director of the MD/MBA and MBS/MBA Programs. He has more than three decades of career experience as a regulator and member of the Senior Executive Service in the US Food and Drug Administration, as a manager and executive in the pharmaceutical industry, including pharmacovigilance, and as a member of the academic community.

Message from the Editors

The COVID-19 pandemic has consumed global attention and caused the medical community to quickly learn how to best diagnose and manage this emerged infectious disease. These unprecedented times have resulted in efforts by the medical community to rapidly organize and publish any and all information regarding COVID-19. While the speedy dissemination of information can help clinicians around the globe potentially better manage their patients, there is also the concern that premature conclusions of efficacy or lack of efficacy may negatively influence care. Studies performed during this pandemic are uniformly falling short of our usual standard of randomized controlled trials with participants matched based on intervention and severity of illness. Overall, most journals have valued the speed to publish the most up-to-date results rather than focus on the significant flaws of these early studies.

At Clinical Therapeutics, we welcome your COVID-19 studies and want to be part of disseminating the most useful information to help clinicians around the world. However, we also want to help raise the bar on the quality of published COVID-19 research. We welcome COVID-19 studies from around the world on any aspect of the infection. While we value new findings, we are particularly interested in studies that attempt to incorporate the high standards we usually expect in clinical research.

View More

A Note of Thanks

March marks yet another transition at Clinical Therapeutics.  Dr. Ravi Jhaveri has stepped down in his role as Co-Editor-in-Chief to pursue other opportunities.  Dr. Jhaveri has been an integral part of Clinical Therapeutics since joining the editorial board in 2015. Initially serving as our Topic Editor in Infectious Diseases, he became Co-Editor-in-Chief in 2020. During his tenure, Dr. Jhaveri has been instrumental in implementing exciting changes to the journal, including our new Conversations with the Editor section and our focus on the social determinants impacting access to emerging treatments and diagnostics. His expertise in infectious diseases became invaluable throughout the COVID-19 pandemic, as he ensured that our readers were provided with accurate, unbiased data on emerging treatments and preventive vaccines.  We will greatly miss Dr. Jhaveri but are thrilled that he will continue to serve on the journal as an emeritus editor. We wish him the very best in all his future endeavors.

Most Read (Last 30 Days)

Most Cited (Previous 3 Years)

Advertisement